Rizatriptan Dosage
For patients aged 12 years or older with normal hepatic function and no cardiovascular contraindications, the recommended starting dose of rizatriptan is 5 mg or 10 mg orally, with the 10 mg dose preferred as it provides superior efficacy with faster onset of action. 1
Standard Dosing Regimen
Initial Dose
- 5 mg or 10 mg orally at migraine onset
- The 10 mg dose is more effective than 5 mg but carries slightly higher risk of adverse effects 2, 1
- Peak concentration reached in 60-90 minutes, faster than most other triptans 2
Redosing Parameters
- If headache returns, a second dose may be given 2 hours after the first dose 1
- Maximum daily dose: 30 mg in any 24-hour period 2, 1
- Safety of treating more than 4 headaches per 30-day period has not been established 1
Formulation Options
Rizatriptan is available as:
- Standard oral tablet (5 mg or 10 mg)
- Orally disintegrating tablet (ODT) - Maxalt MLT (5 mg or 10 mg) 2
The ODT formulation is particularly useful when nausea/vomiting accompanies migraine 2. When taken with water, the ODT shows slightly faster absorption compared to without water 3.
Critical Dosage Adjustment: Propranolol Users
For patients taking propranolol, use only 5 mg rizatriptan, maximum 3 doses (15 mg total) in 24 hours 1. This adjustment is necessary due to drug interaction that increases rizatriptan plasma levels.
Efficacy Data Supporting Dosing
The 10 mg dose demonstrates:
- 71% pain relief at 2 hours (vs 62% with 5 mg, 35% with placebo) 4
- 42% complete pain freedom at 2 hours (vs 33% with 5 mg, 10% with placebo) 4
- Onset of effect as early as 30 minutes with the 10 mg dose 4
- 50% pain-free by 2 hours in 90% of attacks during long-term use 5
Practical Prescribing Principles
Trial multiple attacks before abandoning therapy: Patients should treat 2-3 headache episodes before concluding rizatriptan is ineffective 2. Response can vary between attacks.
Early treatment strategy: When rizatriptan 10 mg ODT is taken early (while pain is still mild), 66.3% achieve pain freedom at 2 hours and 52.2% maintain 24-hour sustained pain freedom 6. This represents superior outcomes compared to treating established moderate-severe pain.
If one triptan fails, try another: Lack of response to one triptan does not predict failure with others 2.
Safety Considerations
Absolute Contraindications
- Coronary artery disease or vasospastic coronary disease
- Uncontrolled hypertension
- Other significant cardiovascular disease 2
- Use within 24 hours of ergot-type medications or other triptans 2
- Concurrent MAOI use 2
Important Caveat
A 2024 study found triptans increased MACE risk in patients with cardiovascular disease or elevated cardiovascular risk (RR 4.00), though absolute incidence remained low (1.48% at 60 days) 7. This reinforces the importance of cardiovascular screening before prescribing.
Common Adverse Effects
- Tachycardia, bradycardia, throat tightness 2
- Dizziness, somnolence, asthenia/fatigue, nausea (dose-related and generally mild) 4, 5
- No increase in adverse events with up to 3 doses within 24 hours 4
Long-Term Use
Rizatriptan maintains consistent efficacy over time without evidence of tachyphylaxis. In a 1-year study treating over 46,000 attacks, the 10 mg dose remained consistently superior to both 5 mg and standard care 5. Long-term safety data in pediatric patients (ages 12-17) over 12 months showed 66% experienced any adverse event, with only 2.3% discontinuing due to adverse effects 8.